Magnesium Potentiates the Vortioxetine’s Effects on Physical Performances and Biological Changes in Exercise-Induced Stress in Rats

Magnesium Potentiates the Vortioxetine’s Effects on Physical Performances and Biological Changes in Exercise-Induced Stress in Rats

<i>Background and objectives:</i> Vortioxetine (VRT) is a relatively new selective serotonin reuptake inhibitor (SSRI) antidepressant and serotonin receptor modulator, approved for the treatment of major depression and generalized anxiety disorder. Depression has been linked with psychom...

Full description

Bibliographic Details
Main Authors:	Paula Alina Fotache, Liliana Mititelu-Tartau, Maria Bogdan, Beatrice Rozalina Buca, Liliana Lacramioara Pavel, Ana-Maria Pelin, Andreea-Daniela Meca, Cosmin-Gabriel Tartau, Gratiela Eliza Popa
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Medicina
Subjects:	vortioxetine brain-derived neurotrophic factor BDNF magnesium chloride rats treadmill test
Online Access:	https://www.mdpi.com/1648-9144/58/10/1363

Similar Items

Assessment of the In Vivo Release and Biocompatibility of Novel Vesicles Containing Zinc in Rats
by: Liliana Mititelu-Tartau, et al.
Published: (2021-07-01)

Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
by: Liliana Mititelu Tartau, et al.
Published: (2021-02-01)

The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin—Characterization and Biocompatibility in Mice
by: Loredana Nicoleta Hilițanu, et al.
Published: (2021-11-01)

The Use of Chitosan-Coated Nanovesicles in Repairing Alcohol-Induced Damage of Liver Cells in Mice
by: Loredana Nicoleta Hilițanu, et al.
Published: (2022-06-01)

Chitosan Soft Matter Vesicles Loaded with Acetaminophen as Promising Systems for Modified Drug Release
by: Loredana Nicoleta Hilițanu, et al.
Published: (2023-12-01)

Experience with vortioxetine in the treatment of post-stroke depression
by: I. A. Strelnikova, et al.
Published: (2020-02-01)

The efficacy of vortioxetine for the delusional disorder of cenesthopathy
by: Shinji Sato, et al.
Published: (2024-03-01)

Experience in the treatment of depressive disorders with vortioxetine after hysterectomy
by: Zoya R. Umahanova, et al.
Published: (2024-05-01)

Zinc Chloride Enhances the Antioxidant Status, Improving the Functional and Structural Organic Disturbances in Streptozotocin-Induced Diabetes in Rats
by: Irina Claudia Anton, et al.
Published: (2022-11-01)

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece
by: E. Papalexi, et al.
Published: (2021-04-01)

Emotional blunting and cognitive profile in elderly depressed patients in treatment with vortioxetine
by: F. Franza, et al.
Published: (2021-04-01)

The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease
by: I. V. Miliukhina
Published: (2020-10-01)

Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients
by: N. V. Filippova, et al.
Published: (2023-06-01)

The effectiveness of vortioxetine in patients with depression in real clinical practice
by: N. N. Petrova
Published: (2022-10-01)

Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
by: K.-S. Oh, et al.
Published: (2022-06-01)

Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study
by: G. Mattingly, et al.
Published: (2021-04-01)

Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
by: A. Galanopoulos, et al.
Published: (2021-04-01)

Vortioxetine‐induced syndrome of inappropriate secretion of antidiuretic hormone: A case report
by: Taro Sasaki, et al.
Published: (2024-06-01)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
by: Zuzana Mlyncekova, et al.
Published: (2023-10-01)

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
by: Marcin Siwek, et al.
Published: (2021-05-01)

Effectiveness of vortioxetine in real-world clinical practice: French cohort results from the global RELIEVE study
by: M. Polosan, et al.
Published: (2022-06-01)

Effectiveness of vortioxetine in real-world clinical practice: Italian cohort results from the global RELIEVE study
by: S. De Filippis, et al.
Published: (2022-06-01)

Vortioxetine for depression treatment in hospital setting: experience from a single psychiatric hospital
by: O. V. Limankin, et al.
Published: (2020-10-01)

Synthesis, Characterization and Biocompatibility Evaluation of Novel Chitosan Lipid Micro-Systems for Modified Release of Diclofenac Sodium
by: Ana-Maria Raluca Pauna, et al.
Published: (2023-02-01)

Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report
by: Yusei Yamaguchi, et al.
Published: (2024-03-01)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
by: Diego Santos García, et al.
Published: (2022-10-01)

Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine
by: Alessandro Cuomo, et al.
Published: (2024-05-01)

Enhanced Stability and In Vitro Biocompatibility of Chitosan-Coated Lipid Vesicles for Indomethacin Delivery
by: Angy Abu Koush, et al.
Published: (2024-12-01)

Vortioxetine usage in an elderly patient with major depressive disorder and accompanied by multiple physical conditions: A case report
by: Xiaoman Wang, et al.
Published: (2023-12-01)

Anxiolytic-like Activity, Antioxidant Properties, and Facilitatory Effects on the Short-Term Memory Retention of Molsidomine in Rats
by: Liliana Mititelu-Tartau, et al.
Published: (2024-02-01)

Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models
by: Andreea Daniela Meca, et al.
Published: (2024-06-01)

Study design of VGOAL-J: an observational, prospective cohort study to assess effectiveness of vortioxetine on goal achievement and work productivity in patients with MDD in Japan
by: K. Watanabe, et al.
Published: (2022-06-01)

The forensic aspects of suicide and neurotrophin factors: a research study
by: Stefania De Simone, et al.
Published: (2024-08-01)

Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain
by: Nazlı Turan Yücel, et al.
Published: (2023-04-01)

Casein and acryl amide complexation and bio-adhesive polymeric nano micelles influence on vortioxetine dissolution, penetration enhancement and in vivo absorption
by: Samaa Abdullah, et al.
Published: (2024-12-01)

Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
by: Chayan K. Manna, et al.
Published: (2023-08-01)

Post-marketing safety surveillance of vortioxetine hydrobromide: a pharmacovigilance study leveraging FAERS database
by: Ying Zhang, et al.
Published: (2025-02-01)

A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality
by: Ye X, et al.
Published: (2024-12-01)

Brain-derived neurotrophic factor (BDNF) as a potential marker of endometriosis: a systematic review and meta-analysis
by: Kyana Jafarabady, et al.
Published: (2024-01-01)

Editorial: Vitamin C from bench to bedside
by: Liliana Mititelu-Tartau, et al.
Published: (2024-04-01)